MINERVA SURGICAL INC (UTRS) Stock Fundamental Analysis

NASDAQ:UTRS • US60343F2056

1.48 USD
-0.07 (-4.52%)
At close: Dec 28, 2023
1.53 USD
+0.05 (+3.38%)
After Hours: 12/28/2023, 8:06:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to UTRS. UTRS was compared to 186 industry peers in the Health Care Equipment & Supplies industry. UTRS has a bad profitability rating. Also its financial health evaluation is rather negative. UTRS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • UTRS had negative earnings in the past year.
  • UTRS had a negative operating cash flow in the past year.
UTRS Yearly Net Income VS EBIT VS OCF VS FCFUTRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -45.95%, UTRS is doing worse than 66.17% of the companies in the same industry.
  • UTRS has a Return On Equity of -164.78%. This is in the lower half of the industry: UTRS underperforms 77.11% of its industry peers.
Industry RankSector Rank
ROA -45.95%
ROE -164.78%
ROIC N/A
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UTRS Yearly ROA, ROE, ROICUTRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 50 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 54.19%, UTRS is in line with its industry, outperforming 50.75% of the companies in the same industry.
  • UTRS's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for UTRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
UTRS Yearly Profit, Operating, Gross MarginsUTRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 50 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • UTRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, UTRS has more shares outstanding
  • UTRS has a worse debt/assets ratio than last year.
UTRS Yearly Shares OutstandingUTRS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 500K 1M
UTRS Yearly Total Debt VS Total AssetsUTRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -6.13, we must say that UTRS is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -6.13, UTRS is not doing good in the industry: 70.65% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 1.37 is on the high side and indicates that UTRS has dependencies on debt financing.
  • UTRS's Debt to Equity ratio of 1.37 is on the low side compared to the rest of the industry. UTRS is outperformed by 82.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Altman-Z -6.13
ROIC/WACCN/A
WACC8.14%
UTRS Yearly LT Debt VS Equity VS FCFUTRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 1.88 indicates that UTRS should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.88, UTRS is not doing good in the industry: 75.62% of the companies in the same industry are doing better.
  • UTRS has a Quick Ratio of 1.02. This is a normal value and indicates that UTRS is financially healthy and should not expect problems in meeting its short term obligations.
  • UTRS's Quick ratio of 1.02 is on the low side compared to the rest of the industry. UTRS is outperformed by 81.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.02
UTRS Yearly Current Assets VS Current LiabilitesUTRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.66% over the past year.
  • Looking at the last year, UTRS shows a small growth in Revenue. The Revenue has grown by 3.07% in the last year.
  • The Revenue has been growing by 24.58% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.40% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, UTRS will show a quite strong growth in Revenue. The Revenue will grow by 10.85% on average per year.
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
UTRS Yearly Revenue VS EstimatesUTRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
UTRS Yearly EPS VS EstimatesUTRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for UTRS. In the last year negative earnings were reported.
  • Also next year UTRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UTRS Price Earnings VS Forward Price EarningsUTRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UTRS Per share dataUTRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • UTRS's earnings are expected to grow with 23.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y23.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • UTRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MINERVA SURGICAL INC

NASDAQ:UTRS (12/28/2023, 8:06:43 PM)

After market: 1.53 +0.05 (+3.38%)

1.48

-0.07 (-4.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-19
Inst Owners0.31%
Inst Owner Change0%
Ins Owners1799.28%
Ins Owner Change0%
Market Cap13.14M
Revenue(TTM)51.69M
Net Income(TTM)-33.45M
Analysts82.86
Price Target3.06 (106.76%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.06%
Min EPS beat(2)20.59%
Max EPS beat(2)45.53%
EPS beat(4)3
Avg EPS beat(4)16.45%
Min EPS beat(4)-6.95%
Max EPS beat(4)45.53%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.42%
Min Revenue beat(2)-11.14%
Max Revenue beat(2)-5.7%
Revenue beat(4)1
Avg Revenue beat(4)-3.51%
Min Revenue beat(4)-11.14%
Max Revenue beat(4)4.81%
Revenue beat(8)1
Avg Revenue beat(8)-2.78%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1250%
EPS NY rev (1m)0%
EPS NY rev (3m)-1750%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.25
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.21
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-4.37
FCFYN/A
OCF(TTM)-4.36
OCFYN/A
SpS5.82
BVpS2.29
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.95%
ROE -164.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.19%
FCFM N/A
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
F-Score2
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.57%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.02
Altman-Z -6.13
F-Score2
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)4.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A
EBIT growth 1Y9.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.05%
EBIT Next 3Y11.17%
EBIT Next 5YN/A
FCF growth 1Y-185.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-198.46%
OCF growth 3YN/A
OCF growth 5YN/A

MINERVA SURGICAL INC / UTRS FAQ

Can you provide the ChartMill fundamental rating for MINERVA SURGICAL INC?

ChartMill assigns a fundamental rating of 2 / 10 to UTRS.


What is the valuation status for UTRS stock?

ChartMill assigns a valuation rating of 1 / 10 to MINERVA SURGICAL INC (UTRS). This can be considered as Overvalued.


What is the profitability of UTRS stock?

MINERVA SURGICAL INC (UTRS) has a profitability rating of 1 / 10.


Can you provide the financial health for UTRS stock?

The financial health rating of MINERVA SURGICAL INC (UTRS) is 1 / 10.